vs
自然阳光（NATR）与Planet Labs PBC（PL）财务数据对比。点击上方公司名可切换其他公司
自然阳光的季度营收约是Planet Labs PBC的1.5倍（$123.8M vs $81.3M），自然阳光净利率更高（3.3% vs -72.8%，领先76.2%），Planet Labs PBC同比增速更快（32.6% vs 4.7%），自然阳光自由现金流更多（$7.6M vs $1.9M），过去两年Planet Labs PBC的营收复合增速更高（17.5% vs 5.6%）
自然阳光产品公司（简称NSP）主营膳食补充剂与个人护理产品的生产制造，产品涵盖草本补充剂、维生素、矿物质制剂等品类。公司总部设于犹他州利希，生产工厂位于犹他州西班牙福克，是该领域知名的健康产品生产商。
Planet Labs PBC（常简称为Planet）是总部位于美国加利福尼亚州旧金山的上市地球影像企业，核心目标是实现全球范围的每日成像，以此监测地表变化、精准识别相关趋势，为多行业的地理数据分析需求提供可靠的数据支持。
NATR vs PL — 直观对比
营收规模更大
NATR
是对方的1.5倍
$81.3M
营收增速更快
PL
高出27.9%
4.7%
净利率更高
NATR
高出76.2%
-72.8%
自由现金流更多
NATR
多$5.7M
$1.9M
两年增速更快
PL
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $123.8M | $81.3M |
| 净利润 | $4.1M | $-59.2M |
| 毛利率 | 72.5% | 57.3% |
| 营业利润率 | 4.3% | -22.6% |
| 净利率 | 3.3% | -72.8% |
| 营收同比 | 4.7% | 32.6% |
| 净利润同比 | 1379.4% | -194.7% |
| 每股收益（稀释后） | $0.23 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NATRPL
| Q4 25 | $123.8M | $81.3M | ||
| Q3 25 | $128.3M | $73.4M | ||
| Q2 25 | $114.8M | $66.3M | ||
| Q1 25 | $113.2M | $61.6M | ||
| Q4 24 | $118.2M | $61.3M | ||
| Q3 24 | $114.6M | $61.1M | ||
| Q2 24 | $110.6M | $60.4M | ||
| Q1 24 | $111.0M | $58.9M |
净利润NATRPL
| Q4 25 | $4.1M | $-59.2M | ||
| Q3 25 | $5.3M | $-22.6M | ||
| Q2 25 | $5.3M | $-12.6M | ||
| Q1 25 | $4.7M | $-35.2M | ||
| Q4 24 | $-321.0K | $-20.1M | ||
| Q3 24 | $4.3M | $-38.7M | ||
| Q2 24 | $1.3M | $-29.3M | ||
| Q1 24 | $2.3M | $-30.1M |
毛利率NATRPL
| Q4 25 | 72.5% | 57.3% | ||
| Q3 25 | 73.3% | 57.6% | ||
| Q2 25 | 71.7% | 55.2% | ||
| Q1 25 | 72.1% | 62.1% | ||
| Q4 24 | 72.0% | 61.2% | ||
| Q3 24 | 71.3% | 52.9% | ||
| Q2 24 | 71.4% | 52.4% | ||
| Q1 24 | 71.2% | 55.2% |
营业利润率NATRPL
| Q4 25 | 4.3% | -22.6% | ||
| Q3 25 | 7.0% | -24.5% | ||
| Q2 25 | 3.7% | -34.4% | ||
| Q1 25 | 5.4% | -31.5% | ||
| Q4 24 | 3.8% | -36.9% | ||
| Q3 24 | 4.6% | -64.8% | ||
| Q2 24 | 5.1% | -57.2% | ||
| Q1 24 | 4.2% | -57.6% |
净利率NATRPL
| Q4 25 | 3.3% | -72.8% | ||
| Q3 25 | 4.2% | -30.8% | ||
| Q2 25 | 4.6% | -19.1% | ||
| Q1 25 | 4.2% | -57.1% | ||
| Q4 24 | -0.3% | -32.8% | ||
| Q3 24 | 3.8% | -63.3% | ||
| Q2 24 | 1.2% | -48.5% | ||
| Q1 24 | 2.1% | -51.1% |
每股收益（稀释后）NATRPL
| Q4 25 | $0.23 | $-0.19 | ||
| Q3 25 | $0.30 | $-0.07 | ||
| Q2 25 | $0.28 | $-0.04 | ||
| Q1 25 | $0.25 | $-0.12 | ||
| Q4 24 | $-0.02 | $-0.07 | ||
| Q3 24 | $0.23 | $-0.13 | ||
| Q2 24 | $0.07 | $-0.10 | ||
| Q1 24 | $0.12 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.9M | $443.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $161.6M | $349.6M |
| 总资产 | $261.1M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NATRPL
| Q4 25 | $93.9M | $443.3M | ||
| Q3 25 | $95.6M | $181.1M | ||
| Q2 25 | $81.3M | $133.5M | ||
| Q1 25 | $86.5M | $118.0M | ||
| Q4 24 | $84.7M | $139.0M | ||
| Q3 24 | $78.7M | $148.3M | ||
| Q2 24 | $68.7M | $107.4M | ||
| Q1 24 | $77.8M | $83.9M |
总债务NATRPL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
股东权益NATRPL
| Q4 25 | $161.6M | $349.6M | ||
| Q3 25 | $166.7M | $435.7M | ||
| Q2 25 | $163.7M | $444.8M | ||
| Q1 25 | $167.1M | $441.3M | ||
| Q4 24 | $161.0M | $464.6M | ||
| Q3 24 | $162.6M | $473.2M | ||
| Q2 24 | $156.4M | $500.3M | ||
| Q1 24 | $159.7M | $518.0M |
总资产NATRPL
| Q4 25 | $261.1M | $1.1B | ||
| Q3 25 | $264.8M | $696.4M | ||
| Q2 25 | $254.9M | $658.4M | ||
| Q1 25 | $252.7M | $633.8M | ||
| Q4 24 | $240.9M | $630.8M | ||
| Q3 24 | $245.3M | $658.4M | ||
| Q2 24 | $235.8M | $674.6M | ||
| Q1 24 | $247.3M | $702.0M |
负债/权益比NATRPL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $28.6M |
| 自由现金流经营现金流 - 资本支出 | $7.6M | $1.9M |
| 自由现金流率自由现金流/营收 | 6.1% | 2.3% |
| 资本支出强度资本支出/营收 | 1.9% | 32.9% |
| 现金转化率经营现金流/净利润 | 2.41× | — |
| 过去12个月自由现金流最近4个季度 | $28.8M | $40.7M |
8季度趋势，按日历期对齐
经营现金流NATRPL
| Q4 25 | $9.9M | $28.6M | ||
| Q3 25 | $18.5M | $67.8M | ||
| Q2 25 | $4.3M | $17.3M | ||
| Q1 25 | $2.6M | $-6.3M | ||
| Q4 24 | $12.2M | $4.1M | ||
| Q3 24 | $9.6M | $-7.9M | ||
| Q2 24 | $1.3M | $-4.3M | ||
| Q1 24 | $2.2M | $-6.8M |
自由现金流NATRPL
| Q4 25 | $7.6M | $1.9M | ||
| Q3 25 | $16.8M | $47.5M | ||
| Q2 25 | $3.0M | $9.2M | ||
| Q1 25 | $1.5M | $-17.9M | ||
| Q4 24 | $10.0M | $-3.6M | ||
| Q3 24 | $7.9M | $-23.0M | ||
| Q2 24 | $-2.0M | $-14.2M | ||
| Q1 24 | $-1.5M | $-15.7M |
自由现金流率NATRPL
| Q4 25 | 6.1% | 2.3% | ||
| Q3 25 | 13.1% | 64.7% | ||
| Q2 25 | 2.6% | 13.9% | ||
| Q1 25 | 1.3% | -29.1% | ||
| Q4 24 | 8.5% | -5.8% | ||
| Q3 24 | 6.9% | -37.6% | ||
| Q2 24 | -1.9% | -23.6% | ||
| Q1 24 | -1.4% | -26.7% |
资本支出强度NATRPL
| Q4 25 | 1.9% | 32.9% | ||
| Q3 25 | 1.3% | 27.6% | ||
| Q2 25 | 1.2% | 12.3% | ||
| Q1 25 | 1.0% | 18.9% | ||
| Q4 24 | 1.9% | 12.5% | ||
| Q3 24 | 1.5% | 24.8% | ||
| Q2 24 | 3.0% | 16.4% | ||
| Q1 24 | 3.3% | 15.1% |
现金转化率NATRPL
| Q4 25 | 2.41× | — | ||
| Q3 25 | 3.46× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | — | ||
| Q1 24 | 0.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
PL
| Defense And Intelligence | $49.4M | 61% |
| Civil Government | $18.8M | 23% |
| Commercial | $13.1M | 16% |
